Han, Xu Kuang, Yijin Chen, Huiyong Liu, Ting Zhang, Ji Liu, Jing
Published in
Current drug targets
Cyclin-dependent kinase inhibitors (CDKIs) are important cell cycle regulators. The CDKI family is composed of the INK4 family and the CIP/KIP family. p19INK4d belongs to the INK4 gene family and is involved in a series of normal physiological activities and the pathogenesis of diseases. Many factors play regulatory roles in the p19INK4d gene expre...
Hu, Baichun Zheng, Xiaoming Wang, Ying Wang, Jian Zhang, Fengjiao
Published in
Current drug targets
The lipid bilayer of the plasma membrane is impermeable to ions, yet changes in the flux of ions across the cell membrane are critical regulatory events in cells. Because of their regulatory roles in a range of physiological processes, such as electrical signaling in muscles and neurons, to name a few, these proteins are one of the most important d...
Campa, Claudio Parodi, Maurizio Battaglia
Published in
Current drug targets
Fu, Jianbo Luo, Yongchao Mou, Minjie Zhang, Hongning Tang, Jing Wang, Yunxia Zhu, Feng
Published in
Current drug targets
Due to its prevalence and negative impacts on both the economy and society, the diabetes mellitus (DM) has emerged as a worldwide concern. In light of this, the label-free quantification (LFQ) proteomics and diabetic marker selection methods have been applied to elucidate the underlying mechanisms associated with insulin resistance, explore novel p...
Wang, Biao Gao, Wenjie Hao, Dingjun
Published in
Current drug targets
Spinal tuberculosis is a common manifestation of extrapulmonary tuberculosis and osteoarticular tuberculosis. Common clinical manifestations include constitutional symptoms, back pain, spinal tenderness, paraplegia, and spinal deformities. They are the common causes of paralysis and could increase the mortality in patients. Most cases of spinal tub...
Mohammad Jafari, Razieh Ala, Moein Goodarzi, Navid Dehpour, Ahmad Reza
Published in
Current drug targets
Nowadays, the breakthrough in different medical branches makes it feasible to designate new methods of drug delivery to achieve the most cost-effective and the least unpleasant consequenceimposing solutions to overcome a wide range of diseases. Nanoparticle (NP) drugs entered the therapeutic system, especially in cancer chemotherapy. These drugs ar...
Bartoszek, Adrian Fichna, Jakub Tarasiuk, Aleksandra Binienda, Agata Fabisiak, Adam Krajewska, Julia B Mosińska, Paula Niewinna, Karolina Salaga, Maciej
Published in
Current drug targets
Colorectal cancer (CRC) is one of the most common cancers worldwide. In developed countries, its mortality remains high, yet the prevalence has established owing to effective screening programs; however due to the westernization of lifestyle, the incidences in many other countries have increased. Although the treatment of CRC has improved in the la...
Dwivedi, Ashish Ranjan Thakur, Amandeep Kumar, Vijay Skvortsova, Ira Kumar, Vinod
Published in
Current drug targets
Resistance to chemotherapy and relapse are major hurdles for the effective treatment of cancer. Major reason for this is a small sub population of cancer stem cells (CSCs) and its microenvironment. CSCs are critical driving force for several types of cancer, such as gastric, colon, breast and many more. Hence, for the complete eradication of cancer...
Zhong, Hui Tang, Hui-Fang Kai, Yin
Published in
Current drug targets
N6-methyladenine RNA modification (m6A) is an RNA methylation modification catalyzed by methyltransferase at the 6th position nitrogen atom of adenine (A), which is the most common chemical modification of eukaryotic messenger RNA (mRNA). Recently, m6A has been found to play an important role in the dynamic regulation of RNA, which is crucial for s...
Junker, Kerstin Eckstein, Markus Fiorentino, Michelangelo Montironi, Rodolfo
Published in
Current drug targets
The immune system is important to control tumor development and progression in humans. However, tumor cells and cells of the tumor microenvironment can induce immune escape mechanisms including activation of immune checkpoints such as PD-1/PD-L1. Based on this knowledge, new immune therapies, including PD-1 and PD-L1 inhibition, have been developed...